TranslatingDPYDgenotype into DPD phenotype: using theDPYDgene activity score

Safety, pharmacokinetics (PK), and cost-effectiveness of upfront genotyping of DPYD in fluoropyrimidine therapy.

(2017) M. J. Deenen et al.   JOURNAL OF CLINICAL ONCOLOGY

Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five US Medical Centers

(2015) Henry M. Dunnenberger et al.   Annual Review of Pharmacology and Toxicology

Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy

(2015) M. Joerger et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Comparative Functional Analysis of DPYD Variants of Potential Clinical Relevance to Dihydropyrimidine Dehydrogenase Activity

(2014) S. M. Offer et al.   CANCER RESEARCH

Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis

(2014) Dan Rosmarin et al.   JOURNAL OF CLINICAL ONCOLOGY

DPYD Variants as Predictors of 5-fluorouracil Toxicity in Adjuvant Colon Cancer Treatment (NCCTG N0147)

(2014) Adam M. Lee et al.   JNCI-Journal of the National Cancer Institute

Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio

(2014) Johanna Sistonen et al.   PHARMACOGENOMICS

Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity

(2013) A Loganayagam et al.   BRITISH JOURNAL OF CANCER

Phenotypic Profiling of DPYD Variations Relevant to 5-Fluorouracil Sensitivity Using Real-time Cellular Analysis and In Vitro Measurement of Enzyme Activity

(2013) S. M. Offer et al.   CANCER RESEARCH

Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing

(2013) K E Caudle et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase splice site variant: the need for further revision of dose and schedule

(2013) Elena Magnani et al.   Internal and Emergency Medicine

Variants in the Dihydropyrimidine Dehydrogenase, Methylenetetrahydrofolate Reductase and Thymidylate Synthase Genes Predict Early Toxicity of 5-Fluorouracil in Colorectal Cancer Patients

(2013) MH Kristensen et al.   JOURNAL OF INTERNATIONAL MEDICAL RESEARCH

The Value of Dihydrouracil/Uracil Plasma Ratios in Predicting 5-Fluorouracil-Related Toxicity in Colorectal Cancer Patients

(2013) MH Kristensen et al.   JOURNAL OF INTERNATIONAL MEDICAL RESEARCH

DPYDIVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis

(2013) Salvatore Terrazzino et al.   PHARMACOGENOMICS

Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency

(2013) M C van Staveren et al.   PHARMACOGENOMICS JOURNAL

Dermatologic Presentations of Orthopedic Pathologies

(2012) Daniel Marchalik et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy

(2011) Yvonne Wettergren et al.   CANCER

Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer

(2011) M. J. Deenen et al.   CLINICAL CANCER RESEARCH

Pharmacogenetics: From Bench to Byte— An Update of Guidelines

(2011) J J Swen et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity

(2011) Ursula Amstutz et al.   PHARMACOGENOMICS

Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity

(2010) André B. P. van Kuilenburg et al.   HUMAN GENETICS

Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine?

(2010) Marzia Del Re et al.   EPMA Journal

Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment

(2009) Ursula Amstutz et al.   PHARMACOGENOMICS

Role of Genetic and Nongenetic Factors for Fluorouracil Treatment-Related Severe Toxicity: A Prospective Clinical Trial by the German 5-FU Toxicity Study Group

(2008) Matthias Schwab et al.   JOURNAL OF CLINICAL ONCOLOGY

Pharmacokinetics of 5-Fluorouracil in Patients Heterozygous for the IVS14+1G > A Mutation in the Dihydropyrimidine Dehydrogenase Gene

(2008) A. B. P. van Kuilenburg et al.   NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS

The dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil

(2008) R. Ben Fredj et al.   PATHOLOGIE BIOLOGIE